The incidence of melanoma is increasing faster than any other form of cancer, and it is responsible for the majority of skin cancer deaths. Patients in whom melanoma is diagnosed at stage I have more than a 95% chance of survival compared with 8-25% with a stage IV diagnosis, highlighting the importance of early and accurate diagnosis. Skin Analytics have crafted a series of AI algorithms that can take a dermascopic image of a skin lesion and help identify skin cancer.
Find your nearest AHSN
A graduate of the DigitalHealth. London Accelerator and then the NHS Innovation Accelerator, Skin Analytics specialises in screening for melanoma and non-melanoma skin cancers. The company invested heavily in technology with the potential to disrupt the process of diagnosis and management of skin cancer, having validated its proprietary Artificial Intelligence (AI) in two large studies.
DigitalHealth.London is a partnership programme established by London's three Academic Health Science Networks (AHSNs) – UCLPartners, Imperial College Health Partners, and Health Innovation Network South London.
Working with RYSE and DigitalHealth.London has given us great access to leading NHS initiatives and those behind them, as well as the financial support needed to get our technology to the point it will positively impact patients and the healthcare service.
Neil Daly, CEO, Skin Analytics
How did the Innovation Exchange help?
Skin Analytics raised £1.6 million funding from RYSE and other investors, supported by the DigitalHealth.London investment programme, to finalise the first prospective clinical study in applying AI to dermatology and secure regulatory approval, and bring on the high calibre team needed to deploy the technology into a variety of patient pathways.
Impact & Outcomes
As winners of the UKBAA Best AI Investment, and the Advance Queensland Ignite Grant in 2018, as well as several other awards, grants and accolades, Skin Analytics is on the right path to expand further into the UK, Australia and New Zealand, private and public, healthcare markets.
The company has entered into primary care agreements as well as commercial contracts with private medical insurers and providers.
Evidence published in leading medical journal JAMA shows that people with suspected skin cancer could be diagnosed using Skin Analytics' AI technology DERM with the same accuracy as clinical specialists. The study, which is the first of its kind to explore the use of AI in dermatology, was led by the Royal Free London NHS Trust to evaluate the clinical assessment of over 1,500 skin lesions in a real-world setting at seven different hospitals.